反应详情

Trans 1-[3-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-cyclopentyl]-3-[5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazin-2-yl]-urea (0.288 g, 0.50 mmol) was dissolved with heating in DMF (10 mL) and placed in a 45° C. oil bath. The flask was evacuated and refilled with nitrogen three times. Hydrazine (0.16 mL, 5.1 mmol) was added via syringe. After 30 minutes AcOH (0.6 mL) was added and the mixture heated for 30 minutes more before being evaporated. MeOH was added, filtered and the filtrate was evaporated. H2O was added, filtered and the filtrate was evaporated. The residue was purified by reverse phase column chromatography (20-80% MeOH in 0.1% aqueous AcOH) to give trans 1-(3-amino-cyclopentyl)-3-[5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazin-2-yl]-urea (0.134 g, 60% yield).

1. customplaced in a 45° C.
2. customThe flask was evacuated
3. additionrefilled with nitrogen three times
4. temperaturethe mixture heated for 30 minutes more
5. custombefore being evaporated
6. additionMeOH was added
7. filtrationfiltered
8. customthe filtrate was evaporated
9. additionH2O was added
10. filtrationfiltered
11. customthe filtrate was evaporated
12. customThe residue was purified by reverse phase column chromatography (20-80% MeOH in 0.1% aqueous AcOH)